IDEAYA Biosciences
IDE196
Metastatic Uveal Melanoma
Countdown
206days
Phase 2 readout · Jan 29, 2027
What's at stake
Phase 2 trial results for IDE196 in Metastatic Uveal Melanoma are due Jan 29, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT03947385: Phase 2 trial, sponsor IDEAYA Biosciences, drug IDE196. Primary completion date 2027-01-29 (estimated).”